Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080452953> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W3080452953 endingPage "754" @default.
- W3080452953 startingPage "747" @default.
- W3080452953 abstract "The sudden outbreak of a novel coronavirus in 2019 in Wuhan, China, that rapidly provoked a global concern, marked as the third attack of corona virus in the human society that affected the global healthcare system as well as the global economy. Until and unless an effective vaccine is discovered against the virus, the pharmacological intervention by different antivirals is in the run for remedy. The aim of this systematic review was to evaluate the role of favipiravir along with its safety and efficacy for the patients who are suffering from severe acute respiratory distress syndrome due to CoronaVirus-2 (SARS-CoV-2) as re-purposeful use. We searched PubMed, EMBASE for randomized controlled trials (RCTs), cilicaltrial.com for registered on going trails to evaluate the pros and cons of using favipiravir in COVID-19. After vigorous searching, screening and sorting of 314 articles for completed and published scientific evidences in electronic database, there were only 2 completed and published randomized control trials (RCT) and 17 ongoing or unpublished trials found until June 2020. The main outcome measures were viral clearance, clinical improvement and adverse events reported and published on 147 patients infected with SARS-CoV2. The 2 completed RCTs showed significantly better treatment effects on disease progression, viral clearance, improved the latency to relief for pyrexia and cough on favipiravir treated patients. Adverse effects caused Favipiravir are mild and manageable. Although 9 more RCTs and cohort studies are supposed to be completed by this time that may unveil some evidence for use of anti-RNA-viral drug favipiravir against influenza or Ebola to re-purposing against COVID-19 as adopted in different treatment guidelines." @default.
- W3080452953 created "2020-09-01" @default.
- W3080452953 creator A5001833216 @default.
- W3080452953 creator A5025303214 @default.
- W3080452953 creator A5041811697 @default.
- W3080452953 creator A5046461679 @default.
- W3080452953 creator A5050748916 @default.
- W3080452953 creator A5069416784 @default.
- W3080452953 date "2020-07-01" @default.
- W3080452953 modified "2023-09-23" @default.
- W3080452953 title "Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2." @default.
- W3080452953 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32844821" @default.
- W3080452953 hasPublicationYear "2020" @default.
- W3080452953 type Work @default.
- W3080452953 sameAs 3080452953 @default.
- W3080452953 citedByCount "5" @default.
- W3080452953 countsByYear W30804529532021 @default.
- W3080452953 countsByYear W30804529532022 @default.
- W3080452953 crossrefType "journal-article" @default.
- W3080452953 hasAuthorship W3080452953A5001833216 @default.
- W3080452953 hasAuthorship W3080452953A5025303214 @default.
- W3080452953 hasAuthorship W3080452953A5041811697 @default.
- W3080452953 hasAuthorship W3080452953A5046461679 @default.
- W3080452953 hasAuthorship W3080452953A5050748916 @default.
- W3080452953 hasAuthorship W3080452953A5069416784 @default.
- W3080452953 hasConcept C126322002 @default.
- W3080452953 hasConcept C168563851 @default.
- W3080452953 hasConcept C177713679 @default.
- W3080452953 hasConcept C18903297 @default.
- W3080452953 hasConcept C197934379 @default.
- W3080452953 hasConcept C2777469322 @default.
- W3080452953 hasConcept C2779134260 @default.
- W3080452953 hasConcept C2779772310 @default.
- W3080452953 hasConcept C3008058167 @default.
- W3080452953 hasConcept C519536355 @default.
- W3080452953 hasConcept C524204448 @default.
- W3080452953 hasConcept C535046627 @default.
- W3080452953 hasConcept C71924100 @default.
- W3080452953 hasConcept C86803240 @default.
- W3080452953 hasConcept C89623803 @default.
- W3080452953 hasConceptScore W3080452953C126322002 @default.
- W3080452953 hasConceptScore W3080452953C168563851 @default.
- W3080452953 hasConceptScore W3080452953C177713679 @default.
- W3080452953 hasConceptScore W3080452953C18903297 @default.
- W3080452953 hasConceptScore W3080452953C197934379 @default.
- W3080452953 hasConceptScore W3080452953C2777469322 @default.
- W3080452953 hasConceptScore W3080452953C2779134260 @default.
- W3080452953 hasConceptScore W3080452953C2779772310 @default.
- W3080452953 hasConceptScore W3080452953C3008058167 @default.
- W3080452953 hasConceptScore W3080452953C519536355 @default.
- W3080452953 hasConceptScore W3080452953C524204448 @default.
- W3080452953 hasConceptScore W3080452953C535046627 @default.
- W3080452953 hasConceptScore W3080452953C71924100 @default.
- W3080452953 hasConceptScore W3080452953C86803240 @default.
- W3080452953 hasConceptScore W3080452953C89623803 @default.
- W3080452953 hasIssue "3" @default.
- W3080452953 hasLocation W30804529531 @default.
- W3080452953 hasOpenAccess W3080452953 @default.
- W3080452953 hasPrimaryLocation W30804529531 @default.
- W3080452953 hasRelatedWork W2080095032 @default.
- W3080452953 hasRelatedWork W2256071216 @default.
- W3080452953 hasRelatedWork W3035166213 @default.
- W3080452953 hasRelatedWork W3128287162 @default.
- W3080452953 hasRelatedWork W3138608407 @default.
- W3080452953 hasRelatedWork W3138706273 @default.
- W3080452953 hasRelatedWork W3165341540 @default.
- W3080452953 hasRelatedWork W3169234433 @default.
- W3080452953 hasRelatedWork W4225153289 @default.
- W3080452953 hasRelatedWork W3113687633 @default.
- W3080452953 hasVolume "29" @default.
- W3080452953 isParatext "false" @default.
- W3080452953 isRetracted "false" @default.
- W3080452953 magId "3080452953" @default.
- W3080452953 workType "article" @default.